biostudies-literatureAlcala NAssociazione Italiana per la Ricerca sul CancroWorld Health OrganizationInstitut National Du CancerLigue Nationale contre le Cancer France GenomiqueFoundation for the National Institutes of HealthNCI NIH HHS3407https://www.ebi.ac.uk/biostudies/studies/S-EPMC6702229biostudies-literatureUnknown10(1)The worldwide incidence of pulmonary carcinoids is increasing, but little is known about their molecular characteristics. Through machine learning and multi-omics factor analysis, we compare and contrast the genomic profiles of 116 pulmonary carcinoids (including 35 atypical), 75 large-cell neuroendocrine carcinomas (LCNEC), and 66 small-cell lung cancers. Here we report that the integrative analyses on 257 lung neuroendocrine neoplasms stratify atypical carcinoids into two prognostic groups with a 10-year overall survival of 88% and 27%, respectively. We identify therapeutically relevant molecular groups of pulmonary carcinoids, suggesting DLL3 and the immune system as candidate therapeutic targets; we confirm the value of OTP expression levels for the prognosis and diagnosis of these disNature communicationsIntegrative and comparative genomic analyses identify clinically relevant pulmonary carcinoid groups and unveil the supra-carcinoids.PMC6702229001R03CA195253IG 19238PRT-K-17-047TABAC 17-022R03 CA195253Leblay NThomas de Montpreville VCuenin CMoonen LPelosi GAlcala NBrustugun OTLantuejoul SMeyer VBlanc-Fournier CViari AGhantous AWright GVoegele CLund-Iversen MRoz LSaenger JMcKay JDGalateau-Salle FSandoval JLe Calvez-Kelm FBrevet MHervas DSertier ASHofman PBrambilla EBrcic LLe Stang NDeleuze JFSpeel EJMHofman VFernandez-Cuesta LPapotti MGField JKHerceg ZPastorino UVignaud JMGabriel AAGBoland ASoltermann AChabrier AFerrari ARussell PAGiffon TGraziano PFoll MClement JHLemaitre NBoyault SAbedi-Ardekani BHernandez-Vargas HAltmuller JPopper HLacomme SToffart ACDurand GDingemans AMCCaux CGirard NStojsic JSozzi GMangiante LDelhomme TMNuernberg PMilione MVolante MOlaso RLorimier PDerks JMuscarella LAfalseIntegrative and comparative genomic analyses identify clinically relevant pulmonary carcinoid groups and unveil the supra-carcinoids.The worldwide incidence of pulmonary carcinoids is increasing, but little is known about their molecular characteristics. Through machine learning and multi-omics factor analysis, we compare and contrast the genomic profiles of 116 pulmonary carcinoids (including 35 atypical), 75 large-cell neuroendocrine carcinomas (LCNEC), and 66 small-cell lung cancers. Here we report that the integrative analyses on 257 lung neuroendocrine neoplasms stratify atypical carcinoids into two prognostic groups with a 10-year overall survival of 88% and 27%, respectively. We identify therapeutically relevant molecular groups of pulmonary carcinoids, suggesting DLL3 and the immune system as candidate therapeutic targets; we confirm the value of OTP expression levels for the prognosis and diagnosis of these dis2019-01-01T00:00:00Z2019 Aug2026-06-04T02:12:41.041Z2019-08-26T07:04:10ZS-EPMC67022293143162010.1038/s41467-019-11276-9